Study of PRAME-TCR-NK Cells for Relapsed/Refractory Myeloid Malignancies
This study is testing a new treatment for people with relapsed or hard-to-treat myeloid malignancies (blood cancers like AML or MDS). The treatment involves special immune cells called PRAME-TCR-NK cells, which are designed to target cancer. You would also receive chemotherapy medicines like cyclophosphamide, fludarabine phosphate, decitabine, and dexamethasone. Researchers want to find the safest and most effective dose of these PRAME-TCR-NK cells. They will also look at how well the treatment works to reduce cancer and how long the modified cells stay in your body. The study is open to adults aged 18 to 80 years old.
- Study design
- This is a Phase I/II study, meaning it first looks for the best dose and then checks how well it works. It plans to enroll 44 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and side effects will be monitored throughout the study, which is expected to average 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jeremy Ramdial, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0